"RNAi Therapeutics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of disease treatment which involves the silencing of genes that are associated with a disease by the process of RNA INTERFERENCE.
| Descriptor ID |
D000067492
|
| MeSH Number(s) |
E02.095.301.250
|
| Concept/Terms |
RNAi Therapeutics- RNAi Therapeutics
- RNAi-Based Therapeutics
- RNAi-Based Therapy
- RNAi Based Therapy
- RNAi-Based Therapies
- Therapies, RNAi-Based
- Therapy, RNAi-Based
- RNAi Therapy
- RNAi Therapies
- Therapies, RNAi
- Therapy, RNAi
|
Below are MeSH descriptors whose meaning is more general than "RNAi Therapeutics".
Below are MeSH descriptors whose meaning is more specific than "RNAi Therapeutics".
This graph shows the total number of publications written about "RNAi Therapeutics" by people in this website by year, and whether "RNAi Therapeutics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "RNAi Therapeutics" by people in Profiles.
-
Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Oct; 167(5):1008-1018.e5.
-
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12; 391(10):913-925.
-
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 Sep 12; 391(10):899-912.
-
RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022 03; 182:114113.
-
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. Genet Med. 2022 03; 24(3):654-662.
-
EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond). 2019 09; 14(17):2315-2338.
-
MicroRNA based theranostics for brain cancer: basic principles. J Exp Clin Cancer Res. 2019 May 29; 38(1):231.
-
Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):32-38.
-
Gene Delivery in Lipid Research and Therapies. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):62-69.
-
SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Cancer Lett. 2019 02 01; 442:310-319.